SNPMiner Trials (Home Page)
Report for SNP rs13333226
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
There is one clinical trial.
Clinical Trials
1 Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension
The hypothesis is based on UMOD rs13333226 genotype, there are two strata of hypertensive patients. The High-UMOD group (AA genotype) has increased UMOD excretion, greater salt sensitivity, HTN, normal eGFR and greater BP response to loop diuretics like furosemide. The Low-UMOD group (G allele) has decreased UMOD excretion, salt resistance, increased eGFR, increased proximal tubular reabsorption of Na (possibly related to increased GFR), a poor BP response to loop diuretics, and possibly diminished function of NKCC2. The High-UMOD strata will have decreased delivery of Na+ to the distal tubule and collecting duct because NKCC2 function is normal and the study hypothesis is that the participants will be more responsive to loop diuretics. In contrast, the Low-UMOD group (G allele) will not show a similar response to loop diuretics. This may be related either to lower Na delivery to the TAL, because of increased proximal tubular reabsorption of Na+, or a suppressed function of NKCC2. The population distribution of the High-UMOD group (AA) is 67%. Our overall objective is to test the hypothesis that hypertensive subjects with uncontrolled HTN open possessing the AA genotype of rs13333226 will be better responders to loop diuretics compared to those possessing the G allele.
NCT03354897 Cardiovascular Diseases Hypertension Drug: Torasemide 5Mg Tablet MeSH:Hypertension Cardiovascular Diseases
HPO:Abnormality of the cardiovascular system Hypertension
Clinical Study of UMOD NKCC2 Interaction on Salt-sensitivity in Hypertension The hypothesis is based on UMOD rs13333226 genotype, there are two strata of hypertensive patients.
Our overall objective is to test the hypothesis that hypertensive subjects with uncontrolled HTN open possessing the AA genotype of rs13333226 will be better responders to loop diuretics compared to those possessing the G allele.
Primary Outcomes
Description: Change in 24h ABPM systolic BP AUC at the end of the 16-week treatment phase compared to baseline
Measure: Change in ABPM Time: 16 weeksSecondary Outcomes
Description: change in 24h ABPM diastolic BP AUC between baseline and the end of treatment
Measure: change in 24h ABPM diastolic BP AUC Time: 16 weeksDescription: change in day time ABPM systolic and diastolic BP AUC between baseline and the end of treatment
Measure: change in day time ABPM systolic and diastolic BP AUC Time: 16 weeksDescription: change in night time ABPM systolic and diastolic BP AUC between baseline and the end of treatment
Measure: change in night time ABPM systolic and diastolic BP AUC Time: 16 weeksDescription: change in HBPM SBP and DBP AUC over the entire study period
Measure: change in HBPM SBP and DBP AUC Time: 16 weeksDescription: changes in serum electrolytes over the entire study period
Measure: changes in serum electrolytes Time: 16 weeks